Tracers / [18F]FDG
[18F]FDG
Also written as 2'-[18F]fluoro-2'-deoxy-D-glucose; 2-deoxy-2-[18F]fluoro-D-glucose; [18F]FDG; [18F]fludeoxyglucose; [18F]fluoro-D-glucose; [18F]Fluorodeoxyglucose; [F-18]FDG
- Radionuclide
- F-18 t½ 109.7 min
- Modality
- PET
- Production route
- Cyclotron liquid target
- Stage
- Approved
- Syntheses indexed
- 164
What it is
- Compound class
- Small molecule (sugar analogue)
- Target / mechanism
- Glucose-transporter (GLUT)-mediated uptake and hexokinase phosphorylation with intracellular metabolic trapping (marker of glucose metabolism) PMID 25452219 / DOI 10.1007/s00259-014-2961-x
- Clinical application
- Oncology staging and response; cardiac viability; neurology; infection and inflammation PMID 25452219 / DOI 10.1007/s00259-014-2961-x; PMID 26060443 / DOI 10.4103/0971-3026.155816
- Theranostic pair
- —
Regulatory status
- FDA
- Yes — 1994; Fludeoxyglucose F 18 Injection; first approval NDA 020306 (SUNY Downstate Medical Center); now 60+ NDA/ANDA holders Drugs@FDA / openFDA drug registry, NDA 020306, approved 1994-08-19 — https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process&searchTerm=fludeoxyglucose
- EMA (centralised)
- No EMA medicines register — no centrally authorised medicine containing fludeoxyglucose (18F); search: https://www.ema.europa.eu/en/medicines?search_api_fulltext=fludeoxyglucose
- Other approvals
- Not centrally authorised by EMA, but holds national marketing authorisations in multiple EU/EEA member states (national / decentralised / mutual-recognition procedures). Example (official national register): France — MetaTrace FDG, fludeoxyglucose (18F), marketing authorisation active since 27/04/2010, holder Siemens Healthcare GmbH.
- Brand names
- Fludeoxyglucose F 18 Injection (USP) — no single proprietary brand; multiple manufacturers
Clinical use
- Typical injected activity
- Weight- and acquisition-time-based (EANM guideline formula); ~200-400 MBq for a typical 70 kg adult, 300-400 MBq for brain PET, not exceeding 530 MBq PMID 25452219 / DOI 10.1007/s00259-014-2961-x
- Uptake time
- 60 min (acceptable range 55-75 min) PMID 25452219 / DOI 10.1007/s00259-014-2961-x
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | — | — | 31595722 2019 J Zhejiang Univ Sci B |
| — | — | — | — | — | — | 31673030 2019 Sci Rep |
| — | — | — | — | — | — | 42273653 2026 Nucl Med Mol Imaging |
| Explora Siemens | fixed tubing | SPE | 55% ± 2% no | >96 | Mannose triflate (1,3,4,6-Tetra-O-acetyl-2-O-trifluoromethanesulfonyl-β-D-mannopyranose) In-house / non-commercial (various) | 40927146 2025 Indian J Nucl Med Siemens Explora FDG-4 module was used for the synthesis of [18]FDG — The decay-uncorrected radiochemical yields are 55% ± 2%. |
| Synthera IBA | — | — | — | — | — | 36760503 2023 Front Microbiol Synthesis of [18F]FDG was by standard nucleophilic substitution using an IBA Synthera module (IBA, Louvaine-la-Neuve, Belgium). |
| — | — | — | — | — | — | 35844642 2022 Front Chem |
| Explora | custom manifold | SPE | approximately 60% or above | over 95% | mannose triflate | 36817206 2022 Indian J Nucl Med Pictures of Explora fluorodeoxyglucose-4 for synthesis of 18F-fluorodeoxyglucose with help of purification column — The average yield of the product was approximately 60% or above. |
| FASTlab 2 GE HealthCare | vendor cassette | SPE | 81.4% ± 4.6% yes | > 95 % | mannose triflate | 35201511 2022 EJNMMI Radiopharm Chem an automated synthesis module (GE FASTLab2) in a hot cell — The synthesis had a combined decay corrected radiochemical yield of 81.4% ± 4.6% from end of bombardment (EOB) to end of synthesis (EOS). |
| F300 (FDG synthesizer) Sumitomo | vendor cassette | SPE | 60 no | >95% | mannose triflate ABX | 34385781 2021 Indian J Nucl Med F300E synthesizer — whereas with F300E synthesizer it is around 60% with synthesis time of 25 min. |
| CFN-MPS100 Sumitomo | custom manifold | SPE | 45 no | >95% | mannose triflate ABX | 34385781 2021 Indian J Nucl Med MPS-100 multipurpose synthesis module — The protocol developed with MPS 100 synthesizer for production of [18F] FDG, yielded approximate 45% (EOB), with synthesis time of around 35 min. |
| FASTlab GE HealthCare | vendor cassette | — | — | — | — | 33805264 2021 Diagnostics (Basel) 18F-FDG was synthesized in accordance with the manufacturer's instructions (GE FASTlab, Chicaco, IL, USA). |
| — | — | — | — | — | — | 33579381 2021 Cancer Imaging FDG was synthesized in house as previously described [21]. |
| FASTlab GE HealthCare | vendor cassette | — | — | — | — | 33391493 2021 Theranostics The glucose analogue [18F]FDG was synthesized using FASTlab FDG cassettes with a phosphate buffer formulation and a GE FASTlab platform (GE Healthcare). |
| TRACERlab MX GE HealthCare | vendor cassette | SPE | 52% no | >90% | mannose triflate | 30363401 2018 EJNMMI Radiopharm Chem manufactured FDG using the GE TRACERLabMX-FDG synthesis module — corresponding to 52% activity yield (AY) |
| FASTlab 2 GE HealthCare | vendor cassette | SPE | 71% no | >90% | mannose triflate | 30363401 2018 EJNMMI Radiopharm Chem deployed the FASTLab 2 modules — corresponding to 71% non-corrected AY |
| FASTlab 2 GE HealthCare | vendor cassette | SPE | 72% no | >90% | mannose triflate | 30363401 2018 EJNMMI Radiopharm Chem Using these cyclotron beam parameters in combination with the DUO cassettes on FASTLab 2, yields of FDG were 957 ± 102 mCi at EOS — corresponding to 72% non-corrected AY (n = 235) |
| F300 (FDG synthesizer) Sumitomo | — | — | — | — | — | 27744544 2017 Ann Nucl Med 18F-FDG was prepared using an 18F-FDG synthesizer F300 (Sumitomo Heavy Industries). |
| — | — | — | — | — | — | 28529632 2017 Theranostics |
| TRACERlab MX | — | — | — | — | — | 27508102 2016 Am J Nucl Med Mol Imaging TRACERLab MXFDG synthesiser (GE Health, USA) using alkalic hydrolysis |
| In-house / custom built | custom manifold | SPE | 56±4% yes | 96% | mannose triflate Sigma-Aldrich | 23474380 2013 Appl Radiat Isot the cell was coupled to a custom-built synthesis apparatus, as shown on the right of Fig. 2 — [18F]FDG with a radiochemical yield of 56±4% (decay corrected, n=4) |
| In-house / custom built in-house | custom manifold | SPE | 41% yes | 97% | mannose triflate ABX | 23999726 2013 Molecules For automated radiosynthesis we used custom-made radiosynthesis robot controlled by LabView software. — Full QC analysis confirmed that the product was [18F]FDG (49 GBq, RCP 97%, RCY 41%). |
| In-house / custom built | custom manifold | SPE | 51±11% yes | >95% | mannose triflate Sigma-Aldrich | 23702795 2013 Appl Radiat Isot using a configuration of one RDM and one PRM module — The decay-corrected radiochemical yield of the non-optimized synthesis was 51±11% (n=11) |
| ELIXYS FLEX/CHEM Sofie Biosciences | vendor cassette | SPE | 65% ± 2% yes | — | Mannose triflate ABX | 23855995 2013 EJNMMI Res the ELIXYS (Sofie Biosciences, Culver City, CA, USA), a disposable cassette-based, automated multi-reactor radiosynthesizer — Decay-corrected radiochemical yield of 65% ± 2% (n = 3) was obtained for this 45-min synthesis. |
| In-house / custom built | — | — | 88 ± 7% (fluorination to FTAG); >95% (hydrolysis to FDG) | — | — | 22210110 2012 Proc Natl Acad Sci U S A We have developed an all-electronic digital microfluidic device for microscale chemical synthesis in organic solvents, operated by electrowetting-on-dielectric (EWOD). — high and reliable radio-fluorination efficiency of [18F]FTAG (88 ± 7%, n = 11) and quantitative hydrolysis to [18F]FDG (> 95%, n = 11) |
| TRACERlab MX GE HealthCare | — | — | — | — | — | 23326067 2011 Indian J Nucl Med using the TRACERlab MXFDG (GE Healthcare, Münster, Germany) |
| In-house / custom built Fluidigm | custom manifold | SPE | 96 | 99.3 | mannose triflate (MT) ABX | 20124050 2010 J Nucl Med the coin-shaped reactor chip is designed to draw its radiosynthesis advantages — Several successful syntheses have delivered just over 100 MBq (3 mCi) of 18F-FDG with yield calculated from 18F-fluoride available for reaction reaching 96%. |
| — | — | — | — | — | — | 32281301 2020 Cancer Med |
| — | — | — | — | — | — | 38843483 2024 J Clin Oncol |
| — | — | — | — | — | — | 41863605 2026 Eur J Nucl Med Mol Imaging |
| FASTlab GE HealthCare | vendor cassette | — | — | — | — | 28529638 2017 Theranostics [18F]FDG was synthesized in-house on a Fastlab synthesis module using [18F]FDG- Fastlab cassettes (GE Medical Systems, Uppsala, Sweden). |
| — | — | — | — | — | — | 23829944 2013 EJNMMI Res |
| — | — | — | — | — | — | 31375567 2020 J Nucl Med |
| — | — | — | — | — | — | 17884682 2007 Lancet Neurol |
| FASTlab GE HealthCare | vendor cassette | — | — | — | — | 34078145 2021 J Cereb Blood Flow Metab a FASTlab platform (GE Healthcare) |
| — | — | — | — | — | — | 35534605 2022 Commun Biol |
| — | — | — | — | — | — | 37079128 2023 Eur J Nucl Med Mol Imaging |
| — | — | — | — | — | — | 41706122 2026 Eur J Nucl Med Mol Imaging |
| — | — | — | — | — | — | 21276856 2011 Neuroimage |
| — | — | — | — | — | — | 22755696 2012 Med Phys |
| — | — | — | — | — | — | 32314956 2020 Elife |
| — | — | — | — | — | — | 37226880 2023 Elife |
| — | — | — | — | — | — | 41464242 2025 Diagnostics (Basel) |
| — | — | — | — | — | — | 36104467 2022 Eur Radiol Exp |
| — | — | — | — | — | — | 41824221 2026 EJNMMI Res |
| — | — | — | — | — | — | 31993925 2020 Mol Imaging Biol |
| — | — | — | — | — | — | 37035658 2023 Front Physiol |
| — | — | — | — | — | — | 41872336 2026 Eur J Nucl Med Mol Imaging |
| TRACERlab FX (model not stated) GE HealthCare | — | — | — | — | — | 42708098 2026 Theranostics [18F]FDG was synthesized using an automatic synthesis module (TracerLab Fx FDG; GE Healthcare) at our hospital |
| — | — | — | — | — | — | 42421909 2026 Chin J Cancer Res |
| — | — | — | — | — | — | 42115250 2026 Sci Rep |
| — | — | — | — | — | — | 41964062 2026 Cancer Imaging |
| — | — | — | — | — | — | 41938288 2026 AACE Endocrinol Diabetes |
| — | — | — | — | — | — | 41689142 2026 Cancer Imaging |
| — | — | — | — | — | — | 41595117 2026 Cancers (Basel) |
| — | — | — | — | — | — | 41557134 2026 EJNMMI Res |
| — | — | — | — | — | — | 41515390 2025 Molecules |
| — | — | — | — | — | — | 41489652 2026 Eur J Nucl Med Mol Imaging |
| — | — | — | — | exceeded 95% | — | 41408360 2025 Cancer Imaging 18F-FDG was produced using a circuit-compatible 18F-FDG synthesis module following standard methods (FDG-N; PET Science & Technology, China). |
| — | — | HPLC | — | >95% | — | 41209215 2025 Quant Imaging Med Surg |
| — | — | — | — | — | — | 40776406 2025 Connect Tissue Res |
| — | — | — | — | — | — | 40365277 2025 Theranostics |
| — | — | — | — | — | — | 40349083 2025 Syst Rev |
| — | — | — | — | — | — | 40064709 2025 Eur J Nucl Med Mol Imaging |
| — | — | — | — | — | — | 39351526 2024 Front Endocrinol (Lausanne) |
| — | — | — | — | — | — | 39327017 2024 J Nucl Med |
| — | — | — | — | — | — | 39207485 2024 Eur J Nucl Med Mol Imaging |
| — | — | — | — | — | — | 39142828 2024 J Nucl Med |
| — | — | — | — | — | — | 38787606 2024 FASEB J |
| — | — | — | — | — | — | 38760451 2024 Sci Rep |
| — | — | — | — | — | — | 37310428 2023 Eur J Nucl Med Mol Imaging |
| — | — | — | — | — | — | 35984529 2022 EJNMMI Res |
| — | — | — | — | — | — | 34417933 2021 EJNMMI Radiopharm Chem |
| — | — | — | — | — | — | 33885241 2020 Radiol Oncol |
| Nuclear Interface Nuclear Interface | — | — | — | — | — | 31107537 2019 Mutagenesis [18F]FDG was radiosynthesized at German Cancer Research Center (DKFZ) in a Nuclear Interface FDG synthesis module using [18F]fluoride obtained by nuclear reaction (18O(p,n)18F) from a Scanditronix MC32NI cyclotron. |
| — | — | — | — | — | — | 26877786 2016 Theranostics |
| — GE HealthCare | — | — | — | — | — | 26843617 2016 Oncotarget [18F]FDG was synthesized in house with a 16 MeV Cyclotron (GE PETtrace 6; GE Healthcare, Milwaukee, USA). |
| — | — | — | 98% for protected [18F]FDG | — | — | 22001413 2012 Appl Radiat Isot The substitutions were carried out in a microfluidic reaction flow cell — 98% for protected [(18)F]FDG |
| — | — | — | 70-90% | — | — | 21989864 2012 Nuklearmedizin |
| — | — | — | — no | — | — | 41875574 2026 Appl Radiat Isot an automated synthesizer (F300) |
| — | — | — | — | — | — | 41667279 2026 J Nucl Med Technol 4 radiology technologists were trained to perform FDG synthesis using a cyclotron and an automated synthesis module |
| — | — | — | 73 ± 6.2 % | >96 % | — | 40349649 2025 Appl Radiat Isot using the AllinOne 36-valve synthesis module — The activity yields for two batches of [18F]FDG were 73 ± 6.2 % and 64 ± 4.7 % (n = 3) |
| — | — | — | 64 ± 4.7 % | >96 % | — | 40349649 2025 Appl Radiat Isot using the AllinOne 36-valve synthesis module — The activity yields for two batches of [18F]FDG were 73 ± 6.2 % and 64 ± 4.7 % (n = 3) |
| — | — | — | — | — | — | 37348257 2023 Appl Radiat Isot |
| — | — | — | — | >95% | — | 35593337 2022 Curr Radiopharm Explora FDG4 module is described |
| — | — | — | — | — | — | 35260243 2022 Semin Nucl Med |
| — | — | — | — | — | — | 33398412 2021 Eur J Nucl Med Mol Imaging |
| — | — | — | — | — | — | 32222731 2020 Hell J Nucl Med |
| — | — | SPE | — | >99% | aminooxy-modified tetrazine | 30380464 2018 Nucl Med Biol |
| — | — | SPE | — | >99% | aminooxy-modified PSMA inhibitor | 30380464 2018 Nucl Med Biol |
| — | — | — | — | — | — | 29100155 2018 Appl Radiat Isot Development of a disposable kit with fully automatic self-shielding reactor for [18F]FDG synthesis. |
| — | — | — | — | — | — | 29956853 2018 Chemistry |
| — | — | — | 97% | — | — | 28431335 2017 Appl Radiat Isot |
| — | — | — | — | — | — | 26924501 2016 Nucl Med Biol A multifunctional synthesis module was employed for the radiosynthesis of (18)F-FDG ((18)F-2-fluorodeoxy glucose) and (18)F-FDS starting from (18)F ion using two-pot three-step fully automated reactions. |
| — | — | — | — | — | — | 27694174 2016 J Nucl Med |
| — | — | — | — | — | — | 27314969 2016 Ann Nucl Med The GE FASTlab radiosynthesis module is routinely used for the production of [(18)F]FDG, utilizing the commercially available phosphate cassettes. |
| — | — | — | — | — | — | 25893383 2015 Eur J Nucl Med Mol Imaging |
| — | — | HPLC | 50% | — | [18O]H2O | 24650573 2014 Appl Radiat Isot an aseptic automated chemistry production and quality control module for production of [(18)F]F(-) and clinical [(18)F]FDG — in an automated synthesis mode (RCY≈50%) |
| — | — | — | 82.9% yes | 99.4% | — | 23318199 2013 J Nucl Med Technol FASTlab 18F-FDG production using phosphate and citrate buffer cassettes — The mean decay-corrected RCYs for (18)F-FDG produced by phosphate and citrate cassettes were 82.9% ± 17.4% and 79.2% ± 5.0%, respectively. |
| — | — | — | 79.2% yes | 99.0% | — | 23318199 2013 J Nucl Med Technol FASTlab 18F-FDG production using phosphate and citrate buffer cassettes — The mean decay-corrected RCYs for (18)F-FDG produced by phosphate and citrate cassettes were 82.9% ± 17.4% and 79.2% ± 5.0%, respectively. |
| — | — | — | 60 ± 5% | — | — | 23208244 2013 Appl Radiat Isot The FDG yield is 60 ± 5% (EOS) with a TracerLab MX (G.E. Healthcare). — The FDG yield is 60 ± 5% (EOS) with a TracerLab MX (G.E. Healthcare). |
| — | — | — | — | — | — | 22785528 2012 Clin Nucl Med |
| — | — | — | — | — | — | 21296149 2011 Eur J Pharm Biopharm |
| — | — | — | — | — | — | 21451323 2011 Health Phys |
| — | — | — | 6.4 percent increase | — | [18O]H2O | 21782460 2011 Appl Radiat Isot the average TracerLab MX [18F]FDG yield — a 6.4 percent increase (p=0.0025) in the average TracerLab MX [18F]FDG yield |
| — | — | — | — | — | — | 21641809 2011 Appl Radiat Isot Tracerlab MX radiochemistry system cassettes used to synthesise [18F]FDG |
| — | — | — | — | — | — | 20346685 2010 Appl Radiat Isot |
| — | — | SPE | more than 60% no | above 99% | 1, 3, 4, 6-tetra-O-acetyl-2-O-trifluoromethanesulfony-beta-D-mannopyranose | 19952408 2009 Zhong Nan Da Xue Xue Bao Yi Xue Ban Automated synthesis of (18)F-FDG was performed by the on-column hydrolysis procedure in TRACERlab FXF-N synthesizer. — The uncorrected radiochemical yield of (18)F-FDG was more than 60% within the total synthesis time shorter than 20 min. |
| — | — | SPE | 88 ± 4% | >97% | 1,3,4,6-tetra-O-acetyl-2-O-trifluoromethanesulphonyl-beta-D-mannopyranose (TATM) | 19037638 2009 Eur J Nucl Med Mol Imaging the performance of a conceptually simple microfluidic device integrated into a fully automated synthesis procedure for in-capillary radiosynthesis (ICR) of clinical grade [(18)F]FDG was evaluated — resulted in a radiochemical yield of 88 +/- 4% within <7 min |
| — | — | — | 73% yes | — | resin-bound perfluoroalkylsulfonate | 19156324 2009 Org Biomol Chem |
| — | — | — | — | — | — | 18632831 2008 J Nucl Med |
| — | — | — | 67.2+/-0.7% (virgin water), 65.5+/-0.9% (repurified water) | — | — | 17459713 2007 Appl Radiat Isot manufactured using a GE Minitrace cyclotron and a GE Mx TracerLab synthesizer — The decrease in [18F]-FDG yield, from 67.2+/-0.7% to 65.5+/-0.9% |
| — | — | — | 60% | — | mannose triflate precursor | 16290944 2006 Appl Radiat Isot using a polymer microreactor chip — 60% radiochemical yield within 4s |
| — | — | — | — | — | — | 16357255 2005 Science We achieved the synthesis of an [(18)F]fluoride-radiolabeled molecular imaging probe, 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG), in an integrated microfluidic device. |
| — | — | — | — | — | — | 15544995 2004 Bull Cancer |
| — | — | — | — | — | — | 15241631 2004 Eur J Nucl Med Mol Imaging |
| — | — | — | — | — | — | 12411554 2002 J Nucl Med |
| — | — | — | — | — | — | 7963752 1994 Int J Card Imaging F-18 labelled FDG is produced by an automated synthesis module yielding 22.2 GBq (600 mCi) FDG. |
| — | — | — | — | — | — | 8152238 1993 J Neurosci Methods |
| — | — | — | 12-17% | 96-99% | tetrabutylammonium [18F]fluoride | 2844702 1988 Int J Rad Appl Instrum A incorporated into our Zymate Laboratory Automation System — The end of synthesis yield (12-17%) |
| — | — | — | approximately 20% EOB | 96-99% | acetyl hypo[18F]fluorite | 3027001 1986 Int J Rad Appl Instrum A A compact autosynthesizer was developed and used successfully for the production of 2-deoxy-2-[18F]fluoro-D-glucose — The yield of 18FDG product using the autosynthesizer and remote manually controlled purification procedures is approximately 20% EOB. |
| — | — | — | — | — | — | 42159908 2026 Jpn J Radiol |
| — | — | — | — | — | — | 39227217 2025 Acad Radiol |
| — | — | — | — | — | — | 40117893 2025 Parkinsonism Relat Disord |
| — | — | — | — | — | — | 37452820 2024 JACC Cardiovasc Imaging |
| — | — | — | — | — | — | 38714019 2024 Comput Med Imaging Graph |
| — | — | — | — | — | — | 36600126 2023 Eur Radiol |
| — | — | — | — | — | — | 32535710 2021 Surg Today |
| — | — | — | — | — | — | 32866778 2020 Phys Med |
| — | — | — | — | — | — | 31119608 2019 Ann Nucl Med |
| — | — | — | — | — | — | 29925748 2018 Nihon Hoshasen Gijutsu Gakkai Zasshi |
| — | — | — | — | — | — | 29790486 2018 Med Pr |
| — | — | — | — | — | — | 27028708 2016 Acta Psychiatr Scand |
| — | — | — | — | — | — | 26585056 2016 J Nucl Med |
| — | — | — | — | — | — | 19280185 2009 Eur J Nucl Med Mol Imaging |
| — | — | — | — | — | — | 17315089 2007 Rev Port Pneumol |
| — | — | — | — | — | — | 16053223 2005 Przegl Lek |
| — | — | — | — | approximately 99% | — | 15701412 2005 Appl Radiat Isot |
| — | — | — | — | — | — | 11696630 2001 J Nucl Med |
| — | — | — | — | — | — | 7790950 1995 J Nucl Med |
| — | — | — | — | — | — | 42710079 2026 Clin Nucl Med |
| — | — | — | — | — | — | 42701315 2026 Hell J Nucl Med |
| — | — | — | — | — | — | 42635770 2026 Eur J Nucl Med Mol Imaging |
| — | — | — | — | — | — | 42624106 2026 Cell Stem Cell |
| — | — | — | — | — | — | 42575751 2026 PET Clin |
| — | — | — | — | — | — | 42573855 2026 J Gastrointest Cancer |
| — | — | — | — | — | — | 42560334 2026 Radiat Prot Dosimetry |
| — | — | — | — | — | — | 42410759 2026 Clin Nucl Med |
| — | — | — | — | — | — | 42341206 2026 Clin Nucl Med |
| — | — | — | — | — | — | 42333406 2026 Clin Nucl Med |
| — | — | — | — | — | — | 42324414 2026 Mol Imaging Biol |
| — | — | — | — | — | — | 42118324 2026 Eur J Nucl Med Mol Imaging |
| — | — | — | — | — | — | 42007813 2026 Clin Nucl Med |
| — | — | — | — | — | — | 42001445 2026 Hell J Nucl Med |
| — | — | — | — | — | — | 41949416 2026 Clin Nucl Med |
| — | — | — | — | — | — | 41869937 2026 Mol Imaging Radionucl Ther |
| — | — | — | — | — | — | 41627842 2026 Clin Nucl Med |
| — | — | — | — | — | — | 40923896 2025 Mol Pharm |
| — | — | — | — | — | — | 40259061 2025 Eur J Nucl Med Mol Imaging |
| — | — | — | — | — | — | 39266292 2024 J Nucl Med |
| — | — | — | — | — | — | 32293704 2020 Endokrynol Pol |
| — | — | — | — | — | — | 32169914 2020 J Nucl Med |
| — | — | — | — | — | — | 22818418 2012 Int J Radiat Oncol Biol Phys |
| — | — | — | — | — | — | 19066925 2009 Arch Gynecol Obstet |
| — | — | — | — | — | — | 8698067 1996 Eur J Nucl Med |
Precursor
- Common precursor
- Mannose triflate PMID 34385781 / PMC8320840
- Suppliers seen in the literature
- ABX (Radeberg, Germany) (mannose triflate)
- Cited suppliers in indexed syntheses
- ABX, In-house / non-commercial (various), Sigma-Aldrich
- Typical final purification
- SPE
Need this precursor?We can point you to suppliers for [18F]FDG, or handle the enquiry for you.
Get in touchQuality control Pharmacopoeial monograph
- Ph. Eur. monograph
- 1325
- USP monograph
- USP monograph: Fludeoxyglucose F 18 Injection (long-standing USP-NF radiopharmaceutical monograph)
How this set was arrived at. Base set per Ph. Eur. 0125 + monograph 1325. Aminopolyether (Kryptofix) + residual solvents (GC) required. Conductometric detection for the sugar (no UV chromophore). Monograph under revision — treat impurity tests as provisional.
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [18F]FDG.
Get in touch